Patents by Inventor Thomas Kreil

Thomas Kreil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11421202
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 23, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wolfgang Mundt, Artur Mitterer, Manfred Reiter, Meinhard Hasslacher, Leopold Grillberger, Thomas Kreil
  • Publication number: 20200277565
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 3, 2020
    Applicants: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang MUNDT, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KREIL
  • Publication number: 20170260498
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Application
    Filed: March 27, 2017
    Publication date: September 14, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Wolfgang MUNDT, Artur MITTERER, Manfred REITER, Meinhard HASSLACHER, Leopold GRILLBERGER, Thomas KREIL
  • Patent number: 9670456
    Abstract: The invention relates to a method for removing a viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. The method comprises subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum about 75 nm. Further, the invention relates to the use of a virus filter in filtration of at least about 24 hours, wherein the virus filter has an effective pore size of maximum about 75 nm for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. In some embodiments the filtration according to the invention operates at a volumetric capacity of at least about 2000 L/m2.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: June 6, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Wolfgang Mundt, Artur Mitterer, Manfred Reiter, Meinhard Hasslacher, Leopold Grillberger, Thomas Kreil
  • Patent number: 8986607
    Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: March 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Patent number: 8377375
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Publication number: 20110206554
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Patent number: 7993580
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Grant
    Filed: August 24, 2004
    Date of Patent: August 9, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel R. Boggs
  • Publication number: 20060257877
    Abstract: A validatable method for determining a photochemically effective dose for inactivating pathogens in a fluid sample is described herein. In particular, the instant invention covers methods for determining a photochemically effective dose sufficient to inactivate pathogens in a biological sample while leaving biologically active substances of interest unaffected. A batch irradiation reactor effective for inactivating pathogens in biological samples is also described.
    Type: Application
    Filed: February 27, 2004
    Publication date: November 16, 2006
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel Boggs
  • Publication number: 20060045796
    Abstract: The present invention relates to a method for determining an effective dose of monochromatic or polychromatic light from one or more light sources to inactivate microorganisms present in a biological fluid, preferably a non-transparent fluid. Moreover, there is provided a method for the inactivation of microorganism in a biological fluid in a flow-through-reactor. Moreover, the invention advantageously provides a flow-through-reactor with one or more thermostated light sources. The invention further provides a method of controlling the light sum dose of monochromatic or polychromatic light emitted from one or more light sources to effectively inactivate microorganisms present in a biological fluid in a batch reactor.
    Type: Application
    Filed: August 24, 2004
    Publication date: March 2, 2006
    Inventors: Heinz Anderle, Peter Matthiessen, Hans-Peter Schwarz, Peter Turecek, Thomas Kreil, Daniel Boggs
  • Publication number: 20030133829
    Abstract: The present invention provides a method for inactivating pathogens in a protein solution. The method includes adding to the protein solution either separately or together as a composition (a) a detergent; and (b) an ester of a di- or tri-carboxylic acid to make a preparation. The ester is generally present in the preparation in a concentration of from about 0.001 to about 2% (w/w). The detergent is typically present in a concentration of about 0.001 to about 2% (w/w). The preparation is incubated for a sufficient amount of time sufficient to inactivate the pathogens.
    Type: Application
    Filed: December 21, 2001
    Publication date: July 17, 2003
    Applicant: Baxter Healthcare Corporation
    Inventors: Heinz Anderle, Martin Spruth, Peter Matthiessen, Peter Turecek, Thomas Kreil, Hans-Peter Schwarz
  • Publication number: 20030103996
    Abstract: The invention relates to a complex comprising an antigen of a microbial or molecular pathogen and mammalian cell constituents in isolated or purified form. A vaccine composition containing the complex, a corresponding pharmaceutical preparation and a method of preparing the complex are also disclosed.
    Type: Application
    Filed: September 26, 2002
    Publication date: June 5, 2003
    Inventors: Martha Eibl, Thomas Kreil, Josef Mannhalter, Johann Eibl, Astrid Kerschbaum, Peter Bruhl